Ustekinumab is a monoclonal antibody that targets IL-12 and IL-23, it is approved for the treatment of plaque psoriasis. Read the latest recommendations on its use.
FDA: TNF blockers increase the risk of lymphoma and other malignancies in children and adolescents. Drugs included: etanercept –Enbrel-, infliximab –Remicade- and adalimumab –HUMIRA-
Dr. Chan explains how biologic therapy (mainly through monoclonal antibodies) is changing the present and future of autoimmune and inflammatory diseases. He illustrates some examples of autoimmune diseases such as: multiple sclerosis, asthma, treatment of rheumatoid arthritis with etanercept, and others.
The UK’s National Institute for Health and Clinical Excellence (NICE) issued yesterday a guidance on the use of rituximab as first line treatment for chronic lymphocytic leukemia.
Etanercept, infliximab and adalimumab are TNF alpha blockers. Learn about TNF alpha in inflammation. Mechanism of action, therapeutic uses and adverse effects profile of these drugs.
This post intends to be a brief and readable overview on what monoclonal antibodies (mAbs) are and some examples of their clinical applications. The following slideshow is a clear and accurate introduction on the topic: (ignore the first slide error message and move to the second)